JP2012516691A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012516691A5 JP2012516691A5 JP2011548607A JP2011548607A JP2012516691A5 JP 2012516691 A5 JP2012516691 A5 JP 2012516691A5 JP 2011548607 A JP2011548607 A JP 2011548607A JP 2011548607 A JP2011548607 A JP 2011548607A JP 2012516691 A5 JP2012516691 A5 JP 2012516691A5
- Authority
- JP
- Japan
- Prior art keywords
- vector
- cell
- nucleic acid
- cdk6
- promoter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09001521.5 | 2009-02-04 | ||
| EP09001521A EP2218784A1 (en) | 2009-02-04 | 2009-02-04 | Vector(s) containing an inducible gene encoding a CDK4/CD6 inhibitor useful for treating neurodegenerative disorders |
| PCT/EP2010/000702 WO2010089122A2 (en) | 2009-02-04 | 2010-02-04 | Vector(s) containing an inducible gene encoding a cdk4/cdk6 inhibitor useful for treating neurodegenerative disorders or diseases associated with an unscheduled activation of the cell cycle |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012516691A JP2012516691A (ja) | 2012-07-26 |
| JP2012516691A5 true JP2012516691A5 (enExample) | 2013-03-21 |
| JP5869884B2 JP5869884B2 (ja) | 2016-02-24 |
Family
ID=40673417
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011548607A Expired - Fee Related JP5869884B2 (ja) | 2009-02-04 | 2010-02-04 | 細胞周期の不定期の活性化に関連する神経変性障害または疾患の治療に有用なｃｄｋ４／ｃｄｋ６阻害剤をコードする誘導性遺伝子を含有するベクター |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20120004277A1 (enExample) |
| EP (2) | EP2218784A1 (enExample) |
| JP (1) | JP5869884B2 (enExample) |
| KR (1) | KR101378353B1 (enExample) |
| CN (1) | CN102356156A (enExample) |
| AU (1) | AU2010211289B2 (enExample) |
| CA (1) | CA2751531A1 (enExample) |
| WO (1) | WO2010089122A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8653324B2 (en) * | 2010-06-11 | 2014-02-18 | Fox Chase Cancer Center | TetO-p16 transgenic mice |
| WO2012050975A2 (en) * | 2010-09-29 | 2012-04-19 | The University Of North Carolina At Chapel Hill | Novel circular mammalian rna molecules and uses thereof |
| KR101255338B1 (ko) * | 2010-12-15 | 2013-04-16 | 포항공과대학교 산학협력단 | 표적 세포에 대한 폴리뉴클레오티드 전달체 |
| AU2012249553A1 (en) | 2011-04-29 | 2013-10-24 | Selecta Biociences, Inc. | Tolerogenic synthetic nanocarriers for allergy therapy |
| MX2015015231A (es) | 2013-05-03 | 2016-07-06 | Selecta Biosciences Inc | Métodos y composiciones para mejorar las células t reguladoras de cd4+. |
| IL292575A (en) * | 2014-09-07 | 2022-06-01 | Selecta Biosciences Inc | Methods and preparations for weakening immune responses by modulating gene expression in an antiviral transfer system |
| EP3368054A4 (en) | 2015-10-28 | 2019-07-03 | Voyager Therapeutics, Inc. | REGULATORY EXPRESSION USING THE ADENO-ASSOCIATED VIRUS (AAV) |
| AU2018236123B2 (en) | 2017-03-11 | 2024-04-18 | Selecta Biosciences, Inc. | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
| CN108319816B (zh) * | 2018-02-27 | 2021-04-23 | 广州大学 | 一种基于基因通路识别小分子核糖核酸的方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19936034C1 (de) * | 1999-07-30 | 2001-01-25 | Univ Leipzig | Rekombiniertes, neuronalspezifisch aktiviertes, transkribierbares lineares DNA-Konstrukt |
| WO2005033277A2 (en) * | 2003-09-29 | 2005-04-14 | University Of Rochester | Methods of modulating cell cycle and cell signaling pathways using biliverdin reductase |
| JP4956427B2 (ja) * | 2004-07-21 | 2012-06-20 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | レンチウイルスベクターおよびその使用 |
| EP1838841A2 (en) * | 2004-12-23 | 2007-10-03 | The Ludwig Institute for Cancer Research | Engineered dopamine neurons and uses thereof |
| US20080300202A1 (en) * | 2006-05-18 | 2008-12-04 | The State of Oregon acting by and through the State Board of Higher Education on behalf of the | Subtractive transgenics |
| US9394538B2 (en) * | 2008-05-07 | 2016-07-19 | Shi-Lung Lin | Development of universal cancer drugs and vaccines |
-
2009
- 2009-02-04 EP EP09001521A patent/EP2218784A1/en not_active Withdrawn
- 2009-02-04 EP EP13159236.2A patent/EP2620447B1/en not_active Not-in-force
-
2010
- 2010-02-04 JP JP2011548607A patent/JP5869884B2/ja not_active Expired - Fee Related
- 2010-02-04 CN CN2010800127623A patent/CN102356156A/zh active Pending
- 2010-02-04 AU AU2010211289A patent/AU2010211289B2/en not_active Ceased
- 2010-02-04 CA CA2751531A patent/CA2751531A1/en not_active Abandoned
- 2010-02-04 US US13/146,592 patent/US20120004277A1/en not_active Abandoned
- 2010-02-04 KR KR1020117020766A patent/KR101378353B1/ko not_active Expired - Fee Related
- 2010-02-04 WO PCT/EP2010/000702 patent/WO2010089122A2/en not_active Ceased
-
2016
- 2016-01-29 US US15/011,092 patent/US20160144054A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012516691A5 (enExample) | ||
| Mueller et al. | PAPD5/7 are host factors that are required for hepatitis B virus RNA stabilization | |
| Wang et al. | Cholesterol 25‐Hydroxylase inhibits SARS‐CoV‐2 and other coronaviruses by depleting membrane cholesterol | |
| JP7698828B2 (ja) | Ｒｎａを編集する方法および組成物 | |
| ES2962434T3 (es) | Procedimientos y composiciones para editar ARN | |
| Nitta et al. | Minimal Purkinje cell-specific PCP2/L7 promoter virally available for rodents and non-human primates | |
| Niepmann | Hepatitis C virus RNA translation | |
| Saleh et al. | Cellular stress induced alterations in microRNA let-7a and let-7b expression are dependent on p53 | |
| US20190351070A1 (en) | Compositions for the inactivation of virus replication and methods of making and using the same | |
| Pellissier et al. | Specific tools for targeting and expression in Müller glial cells | |
| Ni et al. | Lentiviral vector-mediated co-overexpression of VEGF and Bcl-2 improves mesenchymal stem cell survival and enhances paracrine effects in vitro | |
| JP2019089787A5 (enExample) | ||
| JP2008056679A5 (enExample) | ||
| RU2016123086A (ru) | Способы и композиции для лечения болезни хантингтона | |
| Kim et al. | N6-methyladenosine modification of the 5′ epsilon structure of the HBV pregenome RNA regulates its encapsidation by the viral core protein | |
| Kawagishi et al. | Reverse genetics for fusogenic bat-borne orthoreovirus associated with acute respiratory tract infections in humans: Role of outer capsid protein σC in viral replication and pathogenesis | |
| US20210403949A1 (en) | Vector system for expressing regulatory rna | |
| JP2012136542A5 (enExample) | ||
| JP2016537341A5 (enExample) | ||
| JP2008545406A5 (enExample) | ||
| CN112930395A (zh) | 靶向rna的融合蛋白组合物和使用方法 | |
| HK1202434A1 (en) | Virus vectors for highly efficient transgene delivery | |
| FI3546585T3 (fi) | Muokatun intronin käsittäviä nukleiinihappoja käytettäviksi hyperbilirubinemian hoidossa | |
| WO2010127166A4 (en) | Combination anti-hiv vectors, targeting vectors, and methods of use | |
| Dhungel et al. | MicroRNA-regulated gene delivery systems for research and therapeutic purposes |